From a seismic election in the nation's biggest city to a trendy pair of flip-flops, 2025 had some tricky words for some ...

Some of these words have been around - and therefore been mispronounced - for quite a while. Others are viral sensations that ...

The development is expected to have significant implications for India’s generic drugmakers, which are raring to enter the ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

For a limited time, patients can get a steep discount on the popular medications, as long as they’re paying out of pocket Steve Christo/Corbis/Corbis/Getty Ozempic ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

The previous price for Wegovy without insurance was $499. The cash price for popular weight-loss medications Wegovy and Ozempic is dropping by 30% in the U.S. on Monday, according to Novo Nordisk, the ...

Novo Nordisk is temporarily offering doses of Type 2 diabetes drug Ozempic and weight loss medication Wegovy for $199, the drugmaker said Nov. 17. Between Nov. 17 and March 31, self-paying patients of ...

Novo Nordisk (NVO) has cut the price of its weight-loss injection Wegovy by as much as 37% from its launch price in India, as the Danish drugmaker plays catch-up with rival Eli Lilly (LLY), whose ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

Hims & Hers Health (HIMS) traded ~6% higher on Tuesday after the telehealth platform, with its Q3 2025 results, said it is in "active discussions" with Novo Nordisk (NVO) to sell the Danish ...